NCT07634536
Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant
Not Yet Recruiting
PHASE2Ages 18–70InterventionalTreatmentStanford UniversityInvestigator-initiated
~30 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI)FludarabineCyclophosphamideAllogeneic Peripheral Blood Stem Cell Transplantation (PBSCT)Mycophenolate mofetil (MMF)Tacrolimus
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Non-Relapse Mortality (NRM)
Measured over Day 100 after transplantation
+1 more outcome measured
Conditions
NCT07634536
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Stanford University
Palo Alto, Californiastudy coordinator listed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Hany Elmariah, MD · PRINCIPAL_INVESTIGATOR · Stanford University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age 18 to 60 years (inclusive)
HCT Co-Morbidity score (HCT-CI) \< 5 (http://www.qxmd.com/calculate-online/hematology/hct-ci)(31)
Adequate performance status is defined as Karnofsky score ≥ 70%
Patients must be receiving an allogeneic peripheral blood stem cell graft
Patients and selected donor must be HLA typed at high resolution using DNA based typing at the following HLA-loci: HLA-A, -B, -C and DRB1. Donors may be an 8/8 matched sibling donor, 8/8 matched unrelated donor, haploidentical related donor, or 7/8 mismatched unrelated donor. 2. Eligible Diseases (Any one of the following)
Blasts \>5% in the peripheral blood and/or bone marrow after \>2 prior lines of AML directed therapy, present during the trial screening window
Adverse plus risk by AlloHCT Refined ELN Criteria: defined as having complex cytogenetics, TP53 mutation, or MECOM rearrangement confirmed at any time point.(32)
Blasts \>10% in the peripheral blood and/or bone marrow after \>1 prior line of therapy.
TP53 mutation confirmed at any time point
Blasts \>10% in the peripheral blood and/or bone marrow during the trial screening window
TP53 mutation confirmed at any time point 3. Adequate organ function is defined as all of the following:
What this trial measures
- Non-Relapse Mortality (NRM)Day 100 after transplantation
Death without prior disease relapse following allogeneic peripheral blood stem cell transplantation.
- Neutrophil EngraftmentThrough Day 100 after transplantation
Neutrophil engraftment following allogeneic peripheral blood stem cell transplantation.